BCL2L1 is an anti‐apoptotic member of the well‐known family of BCL2 apoptotic regulatory proteins and is a promising prognostic biomarker and drug target in NSCLC [27, 28, 29]. Here, BCL2 is linked to non-small cell lung carcinoma.